Naloxone extended release - SLA Pharma

Drug Profile

Naloxone extended release - SLA Pharma

Alternative Names: Nalcol; Naloxone hydrochloride; Naloxone SR

Latest Information Update: 12 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SLA Pharma
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Constipation

Most Recent Events

  • 14 May 2012 Naloxone extended release is available for partnering as of 14 May 2012.
  • 14 May 2012 Efficacy and adverse events data from a phase II trial in Constipation (opioid-induced) released by SLA Pharma
  • 21 Feb 2012 SLA Pharma completes a phase II trial in Constipation in United Kingdom (EudraCT2009-011853-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top